Andy Yeung
About Andy Yeung
Andy Yeung is the co-founder and Chief Technology Officer of Asher Bio, where he oversees the development of antibody and cytokine candidates and has contributed to advancing multiple preclinical projects into clinical development.
Company: Asher Bio
Andy Yeung co-founded Asher Bio in 2019. He serves as the Chief Technology Officer and Board observer. Asher Bio focuses on the development of antibody and cytokine candidates. Andy takes a central role in initiating drug concepts and leading the engineering and technology development efforts at the company.
Professional Title: CTO and Founder
Andy Yeung holds the title of Chief Technology Officer (CTO) at Asher Bio, a company he co-founded in 2019. In his role, he is a Board observer, playing a crucial role in both strategic decision-making and day-to-day operations concerning drug development and technology projects.
Education and Expertise
Andy Yeung has an extensive educational background in chemical engineering. He earned a Ph.D. in Chemical Engineering and an M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology. He also holds a B.Sc. in Chemical Engineering from the University of Wisconsin-Madison. These academic credentials underpin his expertise in technology development related to biotherapeutics.
Professional Background
Before co-founding Asher Bio, Andy Yeung spent ten years at Pfizer. As the Director of Biotherapeutic Design and Discovery, he led protein engineering efforts for programs in various medical fields, including metabolic diseases, ophthalmology, infectious diseases, and oncology. His efforts significantly contributed to five preclinical research projects advancing through IND-enabling development into the clinic. Additionally, he spent four years in the Antibody Engineering Department at Genentech as a postdoctoral fellow.
Publications and Patents
Andy Yeung has a strong record of scientific contributions, having published numerous articles in peer-reviewed journals. Moreover, he is an inventor on 15 issued patents and patent applications. These accomplishments highlight his role in advancing research and development in the field of biotherapeutics.